Effects of probiotic in generalized anxiety disorder
- Conditions
- Generalized anxiety disorder.Anxiety that is generalized and persistent but not restricted to, or even strongly predominating in, any particular environmental circumstances (i.e. it is free-floating). The dominant symptoms are variable but include complaints of persistent nervousne
- Registration Number
- IRCT201612072394N35
- Lead Sponsor
- Vice-chancellor for research, Iran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 50
DSM-V diagnosed of GAD; Adults between 18 and 65 years old; Willing to participate.
exclusion criteria: Having illness including liver disease and kidney disease, diabetes, immune deficiency, etc; Having psychological illnesses including psychosis, Suicidal ideation, bipolar disorder and major depression; People who are expected to have limited partnerships such as forgetfulness and pregnancy; Taking any medication in the previous 1 month; Taking any medication related to psychiatric diseases including antidepressants, antipsychotics, etc. (maximum of two times per week) and antibiotics in the previous 1 month; Taking any supplement including probiotic supplement, fiber, prebiotics, omega-3, vitamins and minerals in the previous 1 month; Consumption of fermented foods (except yogurt), such as sour cream, acidophilus milk, kefir and some cheeses such as blue vein cheese or Swiss cheese in the previous 1 month; substance abuse; The compliance less than 80%.
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Symptom severity. Timepoint: at baseline, after 1 month and after 2 month. Method of measurement: Beck Anxiety Inventory, Hamilton Rating Scale for anxiety and State-Trait Anxiety Inventory questionnaires.;Plasma acth. Timepoint: at baseline, after 1 month and after 2 month. Method of measurement: Electro-chemiluminescence immunoassay.;Serum cortisol. Timepoint: at baseline, after 1 month and after 2 month. Method of measurement: Chemiluminescence immunoassay.;Quality of life. Timepoint: at baseline, after 1 month and after 2 month. Method of measurement: quality of life, world health organization questionnaire.
- Secondary Outcome Measures
Name Time Method